<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39932306</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-2300</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of international medical research</Title><ISOAbbreviation>J Int Med Res</ISOAbbreviation></Journal><ArticleTitle>Cardiac function and quality of life improvement with fasudil hydrochloride in patients with diabetes post-PCI: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>3000605241311403</StartPage><MedlinePgn>3000605241311403</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">03000605241311403</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/03000605241311403</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We assessed the efficacy of fasudil hydrochloride, a Rho-kinase inhibitor, as adjunct therapy for enhancing cardiac function, managing blood sugar, and improving quality of life in patients with diabetes who have coronary heart disease (CHD) and who underwent percutaneous coronary intervention (PCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized controlled trial including 100 patients with diabetes and CHD who underwent PCI. Participants were randomly assigned to an experimental group receiving fasudil hydrochloride plus standard therapy or a control group receiving standard therapy alone. Treatment outcomes were evaluated over 3 months, focusing on cardiac function, blood sugar levels, and quality of life across physical, social, activities of daily living, and psychological domains.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The experimental group showed significant improvement in cardiac function and blood sugar control, compared with the control group. Additionally, quality of life scores were markedly higher for the experimental group in all evaluated domains.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Fasudil hydrochloride effectively targets endothelial dysfunction and atherosclerosis, contributing to better cardiac performance and metabolic regulation. These effects translate into improved post-PCI quality of life for patients with diabetes and CHD. As an adjunct to standard PCI therapy, fasudil hydrochloride treatment offers a promising strategy for enhancing clinical outcomes in this high-risk patient population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xuejia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yaning</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanjing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Chenghui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Licha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Qiuli</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0007-0213-3711</Identifier><AffiliationInfo><Affiliation>Cardiovascular Zone 2, North China Petroleum Administration General Hospital, Renqiu City, Hebei Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Med Res</MedlineTA><NlmUniqueID>0346411</NlmUniqueID><ISSNLinking>0300-0605</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q0CH43PGXS</RegistryNumber><NameOfSubstance UI="C049347">fasudil</NameOfSubstance></Chemical><Chemical><RegistryNumber>84477-87-2</RegistryNumber><NameOfSubstance UI="D019307">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019307" MajorTopicYN="Y">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary heart disease</Keyword><Keyword MajorTopicYN="N">cardiac function</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">fasudil hydrochloride</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestThe authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39932306</ArticleId><ArticleId IdType="pmc">PMC11815782</ArticleId><ArticleId IdType="doi">10.1177/03000605241311403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang Q, Liang D, Wang F, et al.. Efficacy of electroacupuncture pretreatment for myocardial injury in patients undergoing percutaneous coronary intervention: a randomized clinical trial with a 2-year follow-up[J]. Int J Cardiol 2015; 194: 28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26011261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bova AA, Lapitski&#x12d; DV. [Chronic obstructive pulmonary disease and coronary heart disease: approaches to the treatment of combined pathology]. In Russian. Klin Med (Mosk) 2009; 87: 8&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19348292</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblatt WH. Coronary heart disease. J Miss State Med Assoc 1967; 8: 5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">6043218</ArticleId></ArticleIdList></Reference><Reference><Citation>Darenskaya MA, Kolesnikova LI, Kolesnikov SI. Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction. Bull Exp Biol Med 2021; 171: 179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233182</ArticleId><ArticleId IdType="pubmed">34173093</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013; 36: S67&#x2013;S74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537273</ArticleId><ArticleId IdType="pubmed">23264425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tt K, M&#xfc;ller-Wieland D, Marx N. Diabetes Mellitus and the Heart. Exp Clin Endocrinol Diabetes 2019; 127: S102&#x2013;S104.</Citation><ArticleIdList><ArticleId IdType="pubmed">31860930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis 1998; 32: S89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9820468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PW. Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am 2001; 30: 857&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">11727403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoole SP, Bambrough P. Recent advances in percutaneous coronary intervention. Heart 2020; 106: 1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">32522821</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo DJ, Galli M, Collet JP, et al.. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022; 17: e1371&#x2013;e1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9896394</ArticleId><ArticleId IdType="pubmed">35354550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G, Sheth S, Grines C. Percutaneous coronary intervention: 2017 in review. J Interv Cardiol 2018; 31: 117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">29575110</ArticleId></ArticleIdList></Reference><Reference><Citation>Voll F, Kuna C, Ndrepepa G, et al.. Antithrombotic treatment in primary percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2021; 19: 313&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">33705211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandan SR, Johnson TW. Management of percutaneous coronary intervention complications. Heart 2019; 105: 75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">29760245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloner RA, Chaitman B. Angina and Its Management. J Cardiovasc Pharmacol Ther 2017; 22: 199&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">28196437</ArticleId></ArticleIdList></Reference><Reference><Citation>Katare R, Pearson JT, Lew JK, et al.. Progressive Decrease in Coronary Vascular Function Associated With Type 2 Diabetic Heart Disease. Front Physiol 2018; 9: 696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997806</ArticleId><ArticleId IdType="pubmed">29928236</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">20335313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayfield J. Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician 1998; 58: 1355&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">9803200</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Chakraborty R. Treatment and Diagnosis of Diabetes Mellitus and Its Complication: Advanced Approaches. Mini Rev Med Chem 2015; 15: 1132&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">26459815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleven L, Krell-Roesch J, Nigg CR, et al.. The association between physical activity with incident obesity, coronary heart disease, diabetes and hypertension in adults: a systematic review of longitudinal studies published after 2012. BMC Public Health 2020; 20: 726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238737</ArticleId><ArticleId IdType="pubmed">32429951</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe G, Yamaguchi S, Tomita S, et al.. Fasudil Is an Effective Graft Vasodilator for Gastroepiploic Artery in Coronary Artery Bypass Grafting. Innovations (Phila) 2015; 10: 268&#x2013;272; discussion 272.</Citation><ArticleIdList><ArticleId IdType="pubmed">26360979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai A, Frishman WH. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 2005; 13: 285&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230885</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa K, Yasuda S, Takahashi J, et al.. Involvement of rho-kinase activation in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary artery disease. Circ J 2012; 76: 2552&#x2013;2560.</Citation><ArticleIdList><ArticleId IdType="pubmed">22813839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi Y, Yamada M, Imakiire T, et al.. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192: 595&#x2013;603. 10.1677/joe-06-0045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/joe-06-0045</ArticleId><ArticleId IdType="pubmed">17332527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T, Wakino S, Homma K, et al.. Rho&#x2010;kinase as a molecular target for insulin resistance and hypertension. Faseb J 2006; 20: 169&#x2013;171. 10.1096/fj.05-4197fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4197fje</ArticleId><ArticleId IdType="pubmed">16267124</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicari RM, Chaitman B, Keefe D; Fasudil Study Group et al.. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005; 46: 1803&#x2013;1811. 10.1016/j.jacc.2005.07.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2005.07.047</ArticleId><ArticleId IdType="pubmed">16286163</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi H, Matsui H, Fushimi K, et al.. Association between Preventive Administration of Fasudil Hydrochloride and Post-interventional Neurological Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage. Annals of Clinical Epidemiolog 2020; 2: 107&#x2013;112. 10.37737/ace.2.4_107.</Citation><ArticleIdList><ArticleId IdType="doi">10.37737/ace.2.4_107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>